Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953220614> ?p ?o ?g. }
- W2953220614 endingPage "e950" @default.
- W2953220614 startingPage "e940" @default.
- W2953220614 abstract "BackgroundPaediatric vaccination against influenza can result in indirect protection, by reducing transmission to their unvaccinated contacts. We investigated whether influenza vaccination of children would protect them and their household members in a resource-limited setting.MethodsWe did a cluster-randomised, blinded, controlled study in three villages in India. Clusters were defined as households (ie, dwellings that shared a courtyard), and children aged 6 months to 10 years were eligible for vaccination as and when they became age-eligible throughout the study. Households were randomly assigned (1:1) by a computer-based system to intramuscular trivalent inactivated influenza vaccine (IIV3) or a control of inactivated poliovirus vaccine (IPV) in the beginning of the study; vaccination occurred once a year for 3 years. The primary efficacy outcome was laboratory-confirmed influenza in a vaccinated child with febrile acute respiratory illness, analysed in the modified intention-to-treat population (ie, children who received at least one dose of vaccine, were under surveillance, and had not an influenza infection within 15 days of last vaccine dose). The secondary outcome for indirect effectiveness (surveillance study) was febrile acute respiratory illness in an unvaccinated household member of a vaccine study participant. Data from each year (year 1: November, 2009, to October, 2010; year 2: October, 2010, to October, 2011; and year 3: October, 2011, to May, 2012) were analysed separately. Safety was analysed among all participants who were vaccinated with at least one dose of the vaccine. This trial is registered with ClinicalTrials.gov, number NCT00934245.FindingsBetween Nov 1, 2009, to May 1, 2012, we enrolled 3208 households, of which 1959 had vaccine-eligible children. 1010 households were assigned to IIV3 and 949 households were assigned to IPV. In 3 years, we vaccinated 4345 children (2132 with IIV3 and 2213 with IPV) from 1868 households (968 with IIV3 and 900 with IPV) with 10 813 unvaccinated household contacts. In year 1, influenza virus was detected in 151 (10%) of 1572 IIV3 recipients and 206 (13%) of 1633 of IPV recipients (total IIV3 vaccine efficacy 25·6% [95% CI 6·8–40·6]; p=0·010). In year 2, 105 (6%) of 1705 IIV3 recipients and 182 (10%) of 1814 IPV recipients had influenza (vaccine efficacy 41·0% [24·1–54·1]; p<0·0001). In year 3, 20 (1%) of 1670 IIV3 recipients and 81 (5%) of 1786 IPV recipients had influenza (vaccine efficacy 74·2% [57·8–84·3]; p<0·0001). In year 1, total vaccine efficacy against influenza A(H1N1)pdm09 was 14·5% (–20·4 to 39·3). In year 2, total vaccine efficacy against influenza A(H3N2) was 64·5% (48·5–75·5). Total vaccine efficacy against influenza B was 32·5% (11·3–48·6) in year 1, 4·9% (–38·9 to 34·9) in year 2, and 76·5% (59·4–86·4) in year 3. Indirect vaccine effectiveness was statistically significant only in year 3 (38·1% [7·4–58·6], p=0·0197) when influenza was detected in 39 (1%) of 4323 IIV3-allocated and 60 (1%) of 4121 IPV-allocated household unvaccinated individuals. In the IIV3 group, 225 (12%) of 1632 children in year 1, 375 (22%) of 1718 in year 2, and 209 (12%) of 1673 in year 3 had an adverse reaction (compared with 216 [13%] of 1730, 380 [21%] of 1825, and 235 [13%] of 1796, respectively, in the IPV group). The most common reactions in both groups were fever and tenderness at site. No vaccine-related deaths occurred in either group.InterpretationIIV3 provided variable direct and indirect protection against influenza infection. Indirect protection was significant during the year of highest direct protection and should be considered when quantifying the effect of vaccination programmes.FundingUS Centers for Disease Control and Prevention. Paediatric vaccination against influenza can result in indirect protection, by reducing transmission to their unvaccinated contacts. We investigated whether influenza vaccination of children would protect them and their household members in a resource-limited setting. We did a cluster-randomised, blinded, controlled study in three villages in India. Clusters were defined as households (ie, dwellings that shared a courtyard), and children aged 6 months to 10 years were eligible for vaccination as and when they became age-eligible throughout the study. Households were randomly assigned (1:1) by a computer-based system to intramuscular trivalent inactivated influenza vaccine (IIV3) or a control of inactivated poliovirus vaccine (IPV) in the beginning of the study; vaccination occurred once a year for 3 years. The primary efficacy outcome was laboratory-confirmed influenza in a vaccinated child with febrile acute respiratory illness, analysed in the modified intention-to-treat population (ie, children who received at least one dose of vaccine, were under surveillance, and had not an influenza infection within 15 days of last vaccine dose). The secondary outcome for indirect effectiveness (surveillance study) was febrile acute respiratory illness in an unvaccinated household member of a vaccine study participant. Data from each year (year 1: November, 2009, to October, 2010; year 2: October, 2010, to October, 2011; and year 3: October, 2011, to May, 2012) were analysed separately. Safety was analysed among all participants who were vaccinated with at least one dose of the vaccine. This trial is registered with ClinicalTrials.gov, number NCT00934245. Between Nov 1, 2009, to May 1, 2012, we enrolled 3208 households, of which 1959 had vaccine-eligible children. 1010 households were assigned to IIV3 and 949 households were assigned to IPV. In 3 years, we vaccinated 4345 children (2132 with IIV3 and 2213 with IPV) from 1868 households (968 with IIV3 and 900 with IPV) with 10 813 unvaccinated household contacts. In year 1, influenza virus was detected in 151 (10%) of 1572 IIV3 recipients and 206 (13%) of 1633 of IPV recipients (total IIV3 vaccine efficacy 25·6% [95% CI 6·8–40·6]; p=0·010). In year 2, 105 (6%) of 1705 IIV3 recipients and 182 (10%) of 1814 IPV recipients had influenza (vaccine efficacy 41·0% [24·1–54·1]; p<0·0001). In year 3, 20 (1%) of 1670 IIV3 recipients and 81 (5%) of 1786 IPV recipients had influenza (vaccine efficacy 74·2% [57·8–84·3]; p<0·0001). In year 1, total vaccine efficacy against influenza A(H1N1)pdm09 was 14·5% (–20·4 to 39·3). In year 2, total vaccine efficacy against influenza A(H3N2) was 64·5% (48·5–75·5). Total vaccine efficacy against influenza B was 32·5% (11·3–48·6) in year 1, 4·9% (–38·9 to 34·9) in year 2, and 76·5% (59·4–86·4) in year 3. Indirect vaccine effectiveness was statistically significant only in year 3 (38·1% [7·4–58·6], p=0·0197) when influenza was detected in 39 (1%) of 4323 IIV3-allocated and 60 (1%) of 4121 IPV-allocated household unvaccinated individuals. In the IIV3 group, 225 (12%) of 1632 children in year 1, 375 (22%) of 1718 in year 2, and 209 (12%) of 1673 in year 3 had an adverse reaction (compared with 216 [13%] of 1730, 380 [21%] of 1825, and 235 [13%] of 1796, respectively, in the IPV group). The most common reactions in both groups were fever and tenderness at site. No vaccine-related deaths occurred in either group. IIV3 provided variable direct and indirect protection against influenza infection. Indirect protection was significant during the year of highest direct protection and should be considered when quantifying the effect of vaccination programmes." @default.
- W2953220614 created "2019-06-27" @default.
- W2953220614 creator A5008657518 @default.
- W2953220614 creator A5014022875 @default.
- W2953220614 creator A5045971751 @default.
- W2953220614 creator A5054086444 @default.
- W2953220614 creator A5055991429 @default.
- W2953220614 creator A5058863380 @default.
- W2953220614 creator A5068412542 @default.
- W2953220614 creator A5072214884 @default.
- W2953220614 creator A5072377159 @default.
- W2953220614 creator A5072881103 @default.
- W2953220614 creator A5073936715 @default.
- W2953220614 creator A5074462960 @default.
- W2953220614 creator A5086918063 @default.
- W2953220614 creator A5089602587 @default.
- W2953220614 date "2019-07-01" @default.
- W2953220614 modified "2023-09-23" @default.
- W2953220614 title "Efficacy of inactivated trivalent influenza vaccine in rural India: a 3-year cluster-randomised controlled trial" @default.
- W2953220614 cites W1514125774 @default.
- W2953220614 cites W1963590894 @default.
- W2953220614 cites W1984476090 @default.
- W2953220614 cites W1985583439 @default.
- W2953220614 cites W1990817586 @default.
- W2953220614 cites W2008350826 @default.
- W2953220614 cites W2028587022 @default.
- W2953220614 cites W2034712058 @default.
- W2953220614 cites W2060645165 @default.
- W2953220614 cites W2073734427 @default.
- W2953220614 cites W2078495043 @default.
- W2953220614 cites W2083450984 @default.
- W2953220614 cites W2085975069 @default.
- W2953220614 cites W2105225614 @default.
- W2953220614 cites W2109057963 @default.
- W2953220614 cites W2119503509 @default.
- W2953220614 cites W2125597522 @default.
- W2953220614 cites W2144998000 @default.
- W2953220614 cites W2156869033 @default.
- W2953220614 cites W2172283179 @default.
- W2953220614 cites W2312219549 @default.
- W2953220614 cites W2530113419 @default.
- W2953220614 cites W3103807539 @default.
- W2953220614 cites W4302076775 @default.
- W2953220614 cites W2002309595 @default.
- W2953220614 doi "https://doi.org/10.1016/s2214-109x(19)30079-8" @default.
- W2953220614 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7347003" @default.
- W2953220614 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31200893" @default.
- W2953220614 hasPublicationYear "2019" @default.
- W2953220614 type Work @default.
- W2953220614 sameAs 2953220614 @default.
- W2953220614 citedByCount "15" @default.
- W2953220614 countsByYear W29532206142019 @default.
- W2953220614 countsByYear W29532206142020 @default.
- W2953220614 countsByYear W29532206142021 @default.
- W2953220614 countsByYear W29532206142022 @default.
- W2953220614 countsByYear W29532206142023 @default.
- W2953220614 crossrefType "journal-article" @default.
- W2953220614 hasAuthorship W2953220614A5008657518 @default.
- W2953220614 hasAuthorship W2953220614A5014022875 @default.
- W2953220614 hasAuthorship W2953220614A5045971751 @default.
- W2953220614 hasAuthorship W2953220614A5054086444 @default.
- W2953220614 hasAuthorship W2953220614A5055991429 @default.
- W2953220614 hasAuthorship W2953220614A5058863380 @default.
- W2953220614 hasAuthorship W2953220614A5068412542 @default.
- W2953220614 hasAuthorship W2953220614A5072214884 @default.
- W2953220614 hasAuthorship W2953220614A5072377159 @default.
- W2953220614 hasAuthorship W2953220614A5072881103 @default.
- W2953220614 hasAuthorship W2953220614A5073936715 @default.
- W2953220614 hasAuthorship W2953220614A5074462960 @default.
- W2953220614 hasAuthorship W2953220614A5086918063 @default.
- W2953220614 hasAuthorship W2953220614A5089602587 @default.
- W2953220614 hasBestOaLocation W29532206141 @default.
- W2953220614 hasConcept C126322002 @default.
- W2953220614 hasConcept C159047783 @default.
- W2953220614 hasConcept C164866538 @default.
- W2953220614 hasConcept C168563851 @default.
- W2953220614 hasConcept C176400912 @default.
- W2953220614 hasConcept C199360897 @default.
- W2953220614 hasConcept C22070199 @default.
- W2953220614 hasConcept C2780689484 @default.
- W2953220614 hasConcept C41008148 @default.
- W2953220614 hasConcept C71924100 @default.
- W2953220614 hasConcept C99454951 @default.
- W2953220614 hasConceptScore W2953220614C126322002 @default.
- W2953220614 hasConceptScore W2953220614C159047783 @default.
- W2953220614 hasConceptScore W2953220614C164866538 @default.
- W2953220614 hasConceptScore W2953220614C168563851 @default.
- W2953220614 hasConceptScore W2953220614C176400912 @default.
- W2953220614 hasConceptScore W2953220614C199360897 @default.
- W2953220614 hasConceptScore W2953220614C22070199 @default.
- W2953220614 hasConceptScore W2953220614C2780689484 @default.
- W2953220614 hasConceptScore W2953220614C41008148 @default.
- W2953220614 hasConceptScore W2953220614C71924100 @default.
- W2953220614 hasConceptScore W2953220614C99454951 @default.
- W2953220614 hasIssue "7" @default.
- W2953220614 hasLocation W29532206141 @default.
- W2953220614 hasLocation W29532206142 @default.
- W2953220614 hasLocation W29532206143 @default.